DAX22.497 +0,3%ESt505.160 ±0,0%Top 10 Crypto12,50 +3,1%Dow40.902 +0,6%Nas17.810 +2,1%Bitcoin85.860 +3,2%Euro1,1284 -0,4%Öl62,05 -1,7%Gold3.226 -1,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Microsoft 870747 Rheinmetall 703000 Tesla A1CX3T Amazon 906866 Meta Platforms (ex Facebook) A1JWVX Apple 865985 Palantir A2QA4J Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73 Novo Nordisk A3EU6F Allianz 840400 Deutsche Bank 514000 Lufthansa 823212 BYD A0M4W9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX verabschiedet sich fester in den Feiertag -- Zahlen von Microsoft und Meta überraschen -- VW mit Gewinneinbruch -- Mercedes-Benz erneut mit Gewinneinbußen -- Snap, HENSOLDT, Rheinmetall im Fokus
Top News
Ölpreis, Holzpreis, Silberpreis & Co.: Wie sich die Rohstoffe am Abend entwickeln Ölpreis, Holzpreis, Silberpreis & Co.: Wie sich die Rohstoffe am Abend entwickeln
Goldpreis fällt deutlich: Hoffnung auf Entspannung im Handelsstreit Goldpreis fällt deutlich: Hoffnung auf Entspannung im Handelsstreit
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Bis zu 3,5 % Zinsen: Jetzt Tagesgeld-Angebote vergleichen

Palatin Technologies Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,1700 EUR +0,0056 EUR +3,41 %
FSE
0,2074 USD +0,0204 USD +10,91 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.4,98 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DTUW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6960775020

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTN

Palatin Technologies Aktien News

DatumMeistgelesen
PR NewswirePalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
PR NewswirePalatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
PR NewswirePalatin Appeals NYSE American Notice of Delisting
Wer­bungPalatin Technologies-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswirePalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
PR NewswirePalatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
PR NewswirePalatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
PR NewswirePalatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
PR NewswirePalatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PR NewswirePalatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
PR NewswirePalatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
PR NewswirePalatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
PR NewswirePalatin Provides Update on Anticipated 2025 Corporate Milestones
PR NewswirePalatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
PR NewswirePalatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
PR NewswirePalatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
PR NewswirePalatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
PR NewswirePalatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
PR NewswirePalatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
PR NewswireInflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
PR NewswirePalatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
PR NewswirePalatin Receives Notice of Non-Compliance from NYSE American
PR NewswirePalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
PR NewswirePalatin to Report Fourth Quarter and Fiscal Year End 2024 Results
PR NewswirePalatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
PR NewswireFDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
PR NewswireFirst Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
PR NewswirePalatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
PR NewswirePalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PTN
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PTN
PR NewswirePalatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
PR NewswirePalatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
PR NewswirePalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
PR NewswirePalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
PR NewswirePalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
PR NewswirePalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
PR NewswirePalatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
PR NewswirePalatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Wer­bung

Palatin Technologies News

Palatin Technologies News: auf dieser Seite finden Sie alle Palatin Technologies News und Nachrichten zur Palatin Technologies Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Palatin Technologies News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Palatin Technologies News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.